بدائل البحث:
significant fold » significant force (توسيع البحث), significant co (توسيع البحث), significant all (توسيع البحث)
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث), fold increases (توسيع البحث)
side decrease » sizes decrease (توسيع البحث), fid decreased (توسيع البحث), step decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
significant fold » significant force (توسيع البحث), significant co (توسيع البحث), significant all (توسيع البحث)
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث), fold increases (توسيع البحث)
side decrease » sizes decrease (توسيع البحث), fid decreased (توسيع البحث), step decrease (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), nn decrease (توسيع البحث)
-
281
-
282
-
283
-
284
-
285
-
286
-
287
Data Sheet 1_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.docx
منشور في 2025"…</p>Results<p>In patients with LPD, we found reduced CSA in the right supramarginal gyrus (SMG), right precuneus (PCUN), left inferior parietal lobule (IPL), and left lingual gyrus (LING) compared to RPD, while no significant differences in CT were found between the two groups. …"
-
288
Flow diagram of participants selection.
منشور في 2025"…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
-
289
Minimal data set.
منشور في 2025"…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
-
290
Weighted comparison of baseline characteristics.
منشور في 2025"…Each10 units increase in BRI, ASM/ BMI decreased by 29% (β = −0.29,95% CI: −0.31, −0.28, <i><i>p</i></i> value < 0.0001). …"
-
291
-
292
Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX
منشور في 2024"…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …"
-
293
-
294
-
295
-
296
-
297
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
298
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
299
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
-
300